Nature Reviews Gastroenterology & Hepatology

Article	Citations
Zolbetuximab treatment in metastatic gastric cancer	763
Hybrid EASL Congress 2023	740
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	673
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	627
Mapping neuroimmune interactions in the gut	614
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	556
2023 FDA approvals in gastroenterology and hepatology	462
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	392
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	386
Advancing nutrition science for global health	322
The future of treating pancreatic exocrine insufficiency	317
Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis	309
Nomenclature of HBV core protein-targeting antivirals	306
Western lifestyle, metaflammation and the cell of origin of colon cancer	261
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	254
Black–White disparities across the colorectal cancer care continuum in the USA	253
Large language models for clinical decision support in gastroenterology and hepatology	236
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	235
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health	229
Artificial intelligence and automation in endoscopy and surgery	221
New understanding of hepatobiliary MRI	212
Metastatic pancreatic cancer and the liver	204
Food as medicine in gastrointestinal cancer therapy	203
A crucial Fusobacterium nucleatum clade in colorectal cancer	201
Inflammatory bowel disease in pregnancy and breastfeeding	187

Lessons from incretin-based therapy in MASH and obesity	186
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease	179
The critical role of gut–brain signalling in eating behaviour and obesity	178
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	176
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	170
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	162
Novel insights into chronic HBV infection	162
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	157
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	156
Integrated systems approach to identify environmental factors in intestinal inflammation	145
Characterizing the genomic landscape of colorectal cancer	140
Implications of the evolving knowledge of the genetic architecture of MASLD	139
Probiotics for preterms: sharing complex decision-making	135
Estimating dietary intake from human stool DNA	133
HDCA ameliorates NAFLD in mice	126
Preventing the progression of cirrhosis to decompensation and death	119
Medical therapy of paediatric inflammatory bowel disease	118
SSRIs and depression: role of gut–brain communication	117
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	116
The path to successful hepatitis C elimination in Spain	107
Human intestinal B cells in inflammatory diseases	103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease	102
Proteases in intestinal health and disease	101
Metabolic diseases in the East Asian populations	101
Liver, ageing and disease	97
Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus	97
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	94
Phase III results for first-line treatment for metastatic colorectal cancer	93
ECCO’24	88
Microbiota and colorectal cancer — controlling for confounders challenges associations	87
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	85
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	82
Enteric nervous system transfers stress to the gut	82
Author Correction: Hepatic immune regulation and sex disparities	79
The future of pathology in gastroenterology and hepatology	76
GLP1R agonists in NAFLD: a promising therapy on the horizon	75
HIV-associated gut microbiome influences gut mucosal immunity	73
Human deskilling in medical artificial intelligence: prohibited or permissible under the EU Artificial Intelligence Act?	72
Hepatic inflammatory responses in liver fibrosis	70
NAFLD prevalence in older patients with T2DM	70
Hepatic glucose metabolism in the steatotic liver	69
Transforming the landscape of liver cancer detection and care	68
SMART cancer risk prediction	67
Artificial intelligence in liver cancer — new tools for research and patient management	67
Liver dialysis in ACLF	67
AI predicts pancreatic cancer risk	65
A neurobiotic sense curbs feeding: a new frontier in gut–brain communication	64
A new era in obesity management	64
Nutrient sensing and small intestinal enteric neurons	63
Elucidating the transmission landscape of the human microbiome	63

International collaborative research to improve gallbladder cancer prevention	63
MASLD as a non-communicable disease	62
Nifty new tools for microbiome treatment design	62
Hepatitis E virus: from innate sensing to adaptive immune responses	61
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	57
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	57
Pushing the frontier of gut microbiome health cross-kingdom and cross-organ	57
A novel pathomics signature for gastric cancer	56
Cellular and molecular basis of proximal small intestine disorders	53
Cathepsin S in liver fibrogenesis	53
Steatosis fuels replacement liver metastases in colorectal cancer	53
Bridging the gap: increasing MENA representation in MASLD clinical trials	53
The steatotic liver disease burden paradox: unravelling the key role of alcohol	51
Commensal fungi in intestinal health and disease	50
Features of immune microenvironment associated with colorectal polyp development	49
Therapeutic landscape and future direction of metastatic colorectal cancer	49
Antibiotic-perturbed microbiota and the role of probiotics	49
Microplastics, nanoplastics and liver disease: an emerging health concern?	48
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	47
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	46
Classifying compounds as prebiotics — scientific perspectives and recommendations	44
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	44
Long-term normothermic liver perfusion	42
Author Correction: Improving IBD outcomes in the era of many treatment options	41
Diet-driven microbiome restoration associated with cardiometabolic benefits	41
Alcohol-free and low-strength drinks: friend or foe?	40
Changes in cholera burden across Africa	37
Justice, equity, diversity and inclusion in gastroenterology and hepatology	36
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	35
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	35
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	34
Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’	33
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease	33
Public health policies to prevent alcohol-related liver disease	33
Global epidemiology of cirrhosis — aetiology, trends and predictions	32
A Roadmap for the Human Gut Cell Atlas	31
Gut virome dynamics: from commensal to critical player in health and disease	31
Resmetirom safe for nonalcoholic fatty liver disease	28
Elafibranor in primary biliary cholangitis	28
ECCO’25	28
New target and timing in PDAC immunotherapy?	28
Positive longer-term results for efruxifermin in MASH	28
Digestive Disease Week 2025	27
A resource for the food microbiome and its links with the human microbiome	26
Intermittent fasting for NASH and HCC in mice	26
Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment	26
Digestive Disease Week 2023	26
Deciphering potential implications of dietary microplastics for human health	25
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment	24
Food inequity and insecurity and MASLD: burden, challenges, and interventions	24
Microplastics and nanoplastics in the human gut: from signals to standards	24
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	24
Envisioning how to advance the MASH field	24
HCV direct-acting antiviral therapy adherence in people who inject drugs	23
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	23
Cholangiocarcinoma 2026: status quo, unmet needs and priorities	23
Follow-up of SER-109 for recurrent C. difficile	22
Human liver tissue in a mouse host	21
IL-17A-producing CD8+ T cells in pancreatic cancer	20
Optimizing sacral nerve stimulation to relieve chronic constipation	20
Amitriptyline as second-line treatment for IBS in primary care settings	19
Predicting mortality in cirrhosis	19
Nanoparticles in NAFLD therapeutics	18
Liquid biopsy combined with machine learning predicts early detection in liver disease	18
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	17
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	17
Gastrointestinal health and the environment: a bidirectional relationship	17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	16
Lactylation and HCC progression	16
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16
Precision adherence support for hepatitis C treatment	16
Combination treatment further extends survival	16
Elucidating the nutrient preferences of mouse gut bacteria	15
Liver steatosis and fibrosis in China	15
Neoadjuvant chemotherapy for operable colon cancer	15
Host–pathobiont interactions in Crohn’s disease	14
Biologic agents for IBD come of age as host–microbe interactions emerge	14
Elucidating the link between clonal haematopoiesis and chronic liver disease	14
Positioning therapies for the management of inflammatory bowel disease	14
The mesenteric model of abdominal anatomy	13

Maintaining remission in ulcerative colitis	13
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	13
Actions of thyroid hormones and thyromimetics on the liver	12
Regional organization of nutrient absorption across the small intestine	12
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	12
Synthetic data generation: challenges and perspectives for gastrointestinal medicine	12
Fermented foods and gastrointestinal health: underlying mechanisms	11
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	11
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD	11
Cellular triads in T cell liver tumours	10
Paracellular permeability and tight junction regulation in gut health and disease	10
Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC	10
Connecting with the community	9
A bloody disgrace — time to change patient safety culture	9
Rethinking gastric cancer prevention through an immigrant health lens	9
An expert panel Consensus Statement on ALD without experts by experience	9
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	9
Mechanisms of metastatic colorectal cancer	9
Liver transplantation plus chemotherapy improved survival in patients with colorectal liver metastasis	9
Next-generation enteric neuroscience — fostering the future of the field	9
Precision models in hepatocellular carcinoma	9
Liraglutide treatment in children with obesity	9
Metabotherapy for intestinal disease: using metabolites to prevent and treat disorders of the gut	9
Redefining cancer care: the case for an onco-gastroenterology subspecialty	9
The war on pancreatic cancer: progress and promise	9
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease	9
NAFLD, MAFLD and obesity: brothers in arms?	8
Dietary guidelines for gastrointestinal disorders: key to optimizing practice but more work needed	8
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management	8
The appendix and ulcerative colitis — an unsolved connection	8
Artificial intelligence in inflammatory bowel disease: bridging innovation, implementation and impact	8
Defining ‘gut health’: a leap forward, but still some road to travel	8
Precision nutrition for the prevention and management of inflammatory bowel disease	8
Stigma: a major barrier to hepatitis B elimination	8
Potassium-competitive acid blockers for the management of gastroesophageal reflux disease	8
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction	7
Rhythmicity of infant microbiota and dietary effects	7
Effect of bariatric surgery on risk of oesophagogastric cancer	7
WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials	7
Contrasting aspects of human excreta	7
Understanding the therapeutic toolkit for inflammatory bowel disease	7
Understanding development and cellular plasticity in the pancreas in health and disease	7
What do we mean by gut health?	7
Pouchitis: pathophysiology and management	7
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	7
Human hepatocyte organoids model early NAFLD	7
Positive results for daraxonrasib for previously treated metastatic pancreatic cancer	7
The 3 Ps of IBD today — prevention, pre-diagnosis and participation	7
Fetal liver development and implications for liver disease pathogenesis	7
Metabolic health across the ages: how microbiota members support our well-being	6
Metastasis and pericytes in oesophageal cancer	6
PIEZO1 senses the mechanics of liver regeneration	6
Colonoscopy screening and risk of CRC	6
Combination therapy with methotrexate in paediatric Crohn’s disease	6
The microbiome regulates host metabolic health and diseases through microbial enzymes	6
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	6
Beyond preservation: future machine perfusion for liver assessment and repair	6
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	5
Liver fibrosis with methotrexate — an overestimated risk?	5
Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms	5
Development of MKK4 inhibitors for liver regeneration	5
Novel interventions against alcohol-related liver disease	5
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	5
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	5
Advances in liver and pancreas organoids: how far we have come and where we go next	5
Physical activity and the gut	5
Congenital diarrhoea and enteropathy genetics	4
Ultra-processed diet increases CRC risk	4
Women in endoscopy: leading the way	4
Role of intestinal B cells in NASH and liver fibrosis	4
Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice	4
The global burden of inflammatory bowel disease: from 2025 to 2045	4
Multi-omic links between gut microbiome and cardiovascular disease	4
Diagnosing paediatric coeliac disease	4
CIDEB variants protect against liver disease	4
A prime role for PIEZO2 in DRG neurons in mechanosensation in the gut	4
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome	4
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view	4
Therapeutic developments in pancreatic cancer	4
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	4
Upadacitinib therapy for Crohn’s disease	4
Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC	4
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis	4
MASH-induced senescence and liver cancer	4
Reduction in colorectal cancer incidence by screening endoscopy	4
EASL Congress 2026	4
Bulevirtide for chronic hepatitis D: phase III data	4
Diet–microbiome associations	3
When research on liver fibrosis made the right turn	3
Neutrophils: from IBD to the gut microbiota	3
Environmental effects of surgical procedures and strategies for sustainable surgery	3
Mucosal glycans: key drivers of the development of inflammatory bowel disease and a potential new therapeutic target	3
Intestinal gluconeogenesis: metabolic benefits make sense in the light of evolution	3
Advancing alcohol-related liver disease: from novel biomarkers to refining selection for liver transplantation	3
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance	3